JANX
Janux Therapeutics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeJanux reported improved Q2 2026 financials with narrower losses and new BMS-driven revenue, while advancing its TRACTr pipeline with JANX007, JANX011, and JANX014 progressing through clinical trials. However, the company faces material headwinds including the discontinuation of lead program JANX008 due to dose-limiting musculoskeletal toxicity, a CMO departure after only six months, and significant analyst downgrades (Barclays and UBS cut targets by 51–74%), partially offset by more recent upgrades from Wolfe Research and TD Cowen.
Red flags
- •JANX008 (EGFR-TRACTr program) discontinued in Phase 1a due to dose-limiting musculoskeletal adverse events, removing a potentially major value driver
- •CMO William Go departed under termination-without-cause circumstances after ~6 months in role, signaling internal instability
- •Barclays downgrade with 51.7% price target cut ($29→$14) and UBS downgrade with 74% target cut ($57→$15) based on trial data concerns
- •Significant analyst price target disagreement post-downgrades (range $14–$26 across recent calls), indicating execution and clinical risk uncertainty
Fund 13D/13G Filings (3)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).